Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Bolt Biotherapeutics (BOLT) over the last 5 years, with Q1 2025 value amounting to $288000.0.

  • Bolt Biotherapeutics' Gains from Investment Securities changed N/A to $288000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 935714.29%. This contributed to the annual value of $11.4 million for FY2024, which is 669.36% up from last year.
  • Bolt Biotherapeutics' Gains from Investment Securities amounted to $288000.0 in Q1 2025.
  • In the past 5 years, Bolt Biotherapeutics' Gains from Investment Securities registered a high of $10.7 million during Q4 2023, and its lowest value of -$227000.0 during Q4 2021.
  • Moreover, its 4-year median value for Gains from Investment Securities was $288000.0 (2025), whereas its average is $3.4 million.
  • Over the last 5 years, Bolt Biotherapeutics' Gains from Investment Securities had its largest YoY gain of 4085.86% in 2024, and its largest YoY loss of 4085.86% in 2024.
  • Quarter analysis of 4 years shows Bolt Biotherapeutics' Gains from Investment Securities stood at -$227000.0 in 2021, then surged by 4816.54% to $10.7 million in 2023, then plummeted by 40.86% to $6.3 million in 2024, then plummeted by 95.45% to $288000.0 in 2025.
  • Its Gains from Investment Securities was $288000.0 in Q1 2025, compared to $6.3 million in Q4 2024 and $70000.0 in Q3 2024.